Wolfgang Hanisch

Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia.

Hospira Adelaide Pty Ltd. engages in the provision of biotechnology and research services. It also develops cell therapy technology. It offers biopharmaceutical API products including hGH, a treatment for human growth hormone deficiency; G-CSF, which is used in the treatment of leukemia; and Interferon alpha for chronic hepatitis B and C. The company was founded in 1982 and is headquartered in Thebarton, Australia.

TBG Diagnostics Ltd. engages in the research, development, and manufacture of biopharmaceuticals. It operates through the InVitro Diagnostics segment, which involves in the research of biological drugs and the retail and wholesale of veterinary drugs. The company was founded on September 26, 1989 and is headquartered in Melbourne, Australia.